Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis

BackgroundDupilumab has shown to be an effective and safe treatment for patients with moderate-to-severe atopic dermatitis (AD).ObjectiveTo evaluate the predictive factors of response (PRF) in patients with moderate-to-severe AD treated with dupilumab.MethodsObservational, retrospective and multicentre study conducted on adult patients diagnosed with moderate-to-severe AD treated with dupilumab, with a post-treatment follow-up of at least 16 weeks. The primary endpoints were EASI-75 and the IGA scale at week 52.ResultsA total of 198 patients were included in the analysis. Mean age was 38 +/- 15.1 years and 116 (58.6%) were men. The most prevalent AD-predominant phenotypes were flexural eczema (45.3%), head-and-neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI-75 and 119 (93.0%) achieved an improvement in >= 2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI-75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of >= 2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049).ConclusionsDupilumab was an effective treatment in patients with moderate-to-severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI-75 and an improvement of >= 2 points in the IGA scale, respectively, at week 52.